Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus Vaccine

Adult Inclusion Criteria: * In good health * Available for the duration of the trial * Available for post-inoculation telephone contact * For females, must agree to use effective birth control methods for the duration of the study Seropositive Children Inclusion Criteria: * In good health * Seropositive for HPIV1 * Available for the duration of the study Seronegative Infants and Children Inclusion Criteria: * In good health * Seronegative for HPIV1 antibody * Available for the duration of the study Adult Exclusion Criteria: * Neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease * Condition, in the opinion of the investigator, that will not allow the participant to comply with the protocol * Alcohol or drug abuse * History of anaphylaxis * History of splenectomy * Diagnosis of asthma within 2 years of study entry * HIV-infected * Hepatitis C infection * Hepatitis B infection * Abnormal urinalysis * Known immunodeficiency syndrome * Current use of nasal or systemic steroid medications * Receipt of blood products within 3 months of study entry * Current smoker unwilling to stop smoking for the duration of the study. The decision to exclude a potential subject is made by the investigator based upon the potential subject's medical history and physical examination. * Participation in another investigational vaccine or drug trial within 30 days of receiving the investigational vaccine * Receipt of live vaccine within 4 weeks or a killed vaccine…